

Bayer-THU Collaboration 2023 Call for Applications for Bayer Investigator Award

////////

Collaborate to Cure Hub China Bayer Pharmaceuticals

拜耳处方药中国合作创新中心

November 2023





Introduction



About Bayer Investigator Award

Bayer Investigator Award is presented annually to Tsinghua University Investigators for their scientific excellence in the research field relevant to Bayer Pharma R&D. Selected Bayer Investigators will get the following supports:

- // 150 kCNY Award for each selected Bayer Investigator
- // Connected to Bayer scientists for potential research collaboration discussion

Who May Apply?

Eligibility criteria of the Bayer Investigators are:

- // Full-time employees of TSU at the time of applying and receiving the award
- Working in the School of Life Sciences, School of Medicine, School of Pharmaceutical Sciences or Department of Chemistry, School of Information Science and Technology of Tsinghua
- // Independent of having a project with Bayer or not
- // **Must not** be healthcare professionals, or employed by a hospital due to international compliance requirements
- // Members of the Joint Steering Committee (JSC) may not apply for the award
- // Previous award winners may not apply again





Selection



- Selection of the Bayer Investigators is based on two considerations:
 - // Research excellence, e.g. publication records over the past five years (2018—2023)
 - Research relevance to Bayer's areas of interest, including:
 - <u>Therapeutic areas in Precision Oncology</u> (e.g. Precision molecular oncology, Targeted Radiotherapies, Next-gen Immuno-Oncology, ADCs), Precision cardiorenal diseases (e.g. Heart Failure, Dilated cardiomyopathy, Hypertrophic cardiomyopathy, Chronic kidney disease, Alport, Autosomal dominant kidney disease, Lupus nephritis), Neurology & Rare diseases enabled by cell and gene therapy, and Immunology & Inflammation (e.g. Autoimmune disease).
 - Novel technologies/platforms that enable target identification/drug discovery, specifically structural biology and biophysical methods (eg X-Ray, cryo-EM, AS MS, NMR ect), mRNA technology, disease models, organoids, iPSC-derived cell systems, organ on a chip, multi-omics techniques, bioinformatics, computational capabilities in protein design/protein engineering, biomarker research, nanomedicine, drug delivery, drug metabolism, pharmacokinetics, toxicology, chemistry related expertise in lead generation and optimization.
 - // <u>Therapeutic modalities</u>, e.g. peptide binders, protein degraders, molecular glue, modalities derived from conjugation platforms (antibody, peptide, glyco, radio labelling), RNA therapeutics, cell and gene therapy;
- Selection will be conducted by the Joint Steering Committee (JSC) from both Bayer and Tsinghua University



Application Process



Fill out the Application Form, which includes:

- // A short description of research interests and achievements
- // A list of relevant publications, and publications aligned with Bayer's areas of interest (if any)
- // Curriculum Vitae

Submit your application to Bayer or THU Alliance Managers:

Lidia Li, M.D. (李思妤)

Yuxin Li(李玉鑫)

Collaborate to Cure Hub China Bayer Pharmaceuticals

Tel: +010-85505499 Mobile: +86 15120003110 E-mail: lidia.li@bayer.com General Office of Institute of Biomedicine Tsinghua University

Tel: +86 10 62781816 Mobile: +86 13848615270 E-mail: yuxin-li@mail.tsinghua.edu.cn

Application deadline is Dec 20th, 2023.

Decision letters will be sent out in February 2024

3



Thank you!

